BioSenic is focused on developing innovative treatments for autoimmune and inflammatory diseases, primarily through two product lines: arsenic trioxide-based therapies and cell therapy products. The arsenic trioxide (ATO) treatment, branded as ArsciMed®, targets the immune cascade at its source, offering a unique approach to managing autoimmune conditions. This intravenous formulation has shown promise in clinical studies, particularly for chronic graft versus host disease (cGvHD), systemic lupus erythematosus, and systemic sclerosis. BioSenic is also advancing an oral formulation of arsenic trioxide, known as ArsciCor, which aims to provide similar benefits with improved patient compliance due to its oral administration.

In addition to its arsenic trioxide therapies, BioSenic is developing cell therapy products, specifically the ALLOB program, which utilizes allogeneic osteoblasts derived from healthy donors to promote tissue repair in bone diseases. This innovative approach aims to enhance efficacy while minimizing invasiveness compared to traditional surgical methods. Both product lines are manufactured under stringent Good Manufacturing Practice (GMP) standards, and BioSenic has established a robust intellectual property portfolio to protect its technologies. The company is committed to addressing unmet medical needs in the field of autoimmune diseases and tissue repair, with ongoing clinical studies and a focus on regulatory compliance to bring these therapies to market.

Belgium

BioSenic is an innovative company with the objective of addressing important unmet medical needs in the areas of immunity, auto-immune diseases and organ repair.

BioSenic

Company Details